TRB Chemedica UK Ltd

What TRB Chemedica UK Ltd does

TRB Chemedica UK Ltd is a UK-incorporated, wholly-owned subsidiary of Swiss healthcare group TRB Chemedica International, operating from Newcastle-under-Lyme, Staffordshire. Founded in July 2002, the company has grown from two employees to approximately 15 staff and serves NHS and private healthcare providers across the UK and Ireland. It functions as a specialty medical-device distributor, channelling a portfolio of proprietary sodium-hyaluronate products, ultrasound imaging systems and surgical biologics to rheumatologists, orthopaedic surgeons, ophthalmologists, sports-medicine practitioners and physiotherapists.

The company's product strategy is anchored in hyaluronic-acid (sodium-hyaluronate) technology, deployed across four clinical verticals. In musculoskeletal medicine, the OSTENIL range covers viscosupplementation for osteoarthritis of large joints (OSTENIL, OSTENIL PLUS with mannitol stabilisation for single-injection use), small joints (OSTENIL MINI) and tendon disorders (OSTENIL TENDON). In ophthalmology, the VISMED family of preservative-free, hypotonic (150 mOsm/L) eye drops addresses dry eye disease at multiple severity levels using a patented citrate formulation that prevents corneal calcification. The surgical portfolio comprises VISCOSEAL (synovial fluid replacement for arthroscopy) and ArthroZheal PRF (a platelet-derived growth factor matrix for tissue regeneration, sourced under exclusive agreement with Vivostat A/S). In ultrasound, the company distributes Clarius HD3 wireless handheld scanners (L7, L15, L20 models) with AI-powered anatomical overlays, plus Mindray portable systems and Usono's ProbeFix Dynamic. Manufacturing is performed by the Swiss parent and EU partners; the UK entity's role is distribution, marketing, regulatory stewardship and clinical-evidence curation under ISO 9001:2015 and MDR frameworks.

Revenue is generated on a pay-as-you-go unit-pricing basis across B2B and B2C channels. Distribution occurs through a field-sales team visiting clinics, authorised wholesalers, a credit-account programme for repeat NHS and private buyers, and a direct e-commerce storefront shipping via Royal Mail and UPS within the UK (and to Ireland, with customs duties). Customer-acquisition relies on participation in roughly fifteen UK medical conferences (MIOS, BOA Annual Congress, SEMS, MSK Wrightington, etc.), the Ostenil Approved Clinic referral network, virtual representative consultations, and digital content (SmPCs, clinical studies, condition-education blogs) targeted at healthcare professionals. Pricing is denominated in GBP inclusive of VAT, with OSTENIL at £36.41 per 20mg/2ml syringe, OSTENIL PLUS at £85.80, Clarius L7 scanners starting at £3,545 and Clarius L20 at £5,070+. The company is privately held with no external institutional investment disclosed.

Name

TRB Chemedica UK Ltd

Legal name

TRB Chemedica (UK) Ltd

Website

https://trbchemedica.co.uk

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1–10 employees

Short description

TRB Chemedica UK Ltd is a wholly-owned UK subsidiary of Swiss group TRB Chemedica International, distributing sodium-hyaluronate medical devices (OSTENIL, VISMED, VISCOSEAL), ultrasound scanners (Clarius, Usono, Mindray) and surgical biologics (ArthroZheal) to NHS and private healthcare professionals across the UK and Ireland.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Ophthalmic Goods Merchant Wholesalers (423460)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Ophthalmic Goods (3851), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

akta.pro secondary industries

Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL), Oculoplastics & Lacrimal Surgical Devices (Ptosis/Orbital Tools, DCR/Lacrimal Stents, Facial Implants) (HLAHAJAL)

Keywords

• Viscosupplementation products
• Ophthalmic medical devices
• Dry eye treatments
• Musculoskeletal ultrasound scanners
• Hyaluronic acid injections

Headquarters

HQ city

Newcastle-under-Lyme

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Medical Device Distribution: TRB Chemedica UK generates revenue through the distribution of proprietary medical devices, primarily viscosupplementation products (OSTENIL range), ophthalmic products (VISMED range), ultrasound scanners, and surgical products. Revenue comes from sales to healthcare providers, clinics, and through authorised wholesalers.
2. Proprietary Product Sales: Sales of company-branded products including OSTENIL, VISMED, VISCOSEAL, HAXL One, REMOGEN Omega, and Clarius ultrasound scanners. Products are sold directly to approved clinics and through authorised wholesalers.
3. Distribution Partnerships: Revenue from distribution partnerships including Clarius ultrasound scanners, Mindray portable machines, Usono ProbeFix Dynamic, Vivostat/ArthroZheal products, and HAXL One.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

TRB Chemedica UK Ltd is the UK and Ireland distribution subsidiary of Swiss healthcare group TRB Chemedica International, distributing and marketing proprietary medical devices based on highly purified sodium hyaluronate. The portfolio spans intra-articular and peritendinous viscosupplementation injections (OSTENIL range, HAXL One), preservative-free hypotonic dry eye drops (VISMED range, REMOGEN OMEGA), arthroscopic surgical solutions (VISCOSEAL, ArthroZheal PRF), and wireless point-of-care ultrasound scanners (Clarius HD3).

Product overview

TRB Chemedica UK Ltd operates as a distributor and marketer of proprietary medical devices and pharmaceutical products in the musculoskeletal, ophthalmology, and orthopaedic sectors. The product portfolio is organised into four clinical domains: (1) Musculoskeletal — the OSTENIL Range of intra-articular and peritendinous sodium hyaluronate injections (OSTENIL 20mg/2ml, OSTENIL PLUS 40mg with mannitol single-injection, OSTENIL MINI 10mg for small joints, OSTENIL TENDON 40mg for tendons, and HAXL One); (2) Ophthalmology — VISMED family of preservative-free hypotonic sodium hyaluronate eye drops in multiple concentrations (VISMED 0.18%, VISMED GEL 0.3%, VISMED GEL MULTI, VISMED LIGHT 0.1%) plus REMOGEN OMEGA; (3) Surgical — VISCOSEAL synovial fluid replacement for arthroscopy irrigation and ArthroZheal PRF bioactive matrix for tissue healing; (4) Ultrasound — Clarius HD3 wireless handheld scanners (L7, L15, L20) for MSK diagnostic imaging and procedure guidance, plus Clarius accessories. The company also distributes Usono ProbeFix Dynamic ultrasound and Mindray portable ultrasound devices.

Differentiator

Problem solved

Functional benefit

Brands

• OSTENIL: Range of sodium hyaluronate injections for treatment of osteoarthritis in joints (OSTENIL, OSTENIL Plus, OSTENIL Mini, OSTENIL Tendon)
• VISMED
• VISCOSEAL
• ArthroZheal

Products and services

• OSTENIL Intra-articular injection of 20mg/2ml sodium hyaluronate administered as a course of 3–5 weekly injections for osteoarthritis of large synovial joints (knee, hip, shoulder). Effects typically last up to 12 months. Prescribed and administered by healthcare professionals.
• OSTENIL PLUS Single-injection intra-articular viscosupplement of 40mg/2ml sodium hyaluronate with mannitol as a free-radical scavenger to stabilise HA chains. Designed for knee and hip osteoarthritis, condensing the treatment cycle into one injection.
• OSTENIL MINI Lower-dose intra-articular injection of 10mg/1ml sodium hyaluronate for osteoarthritis in small synovial joints such as finger, toe, thumb, and temporomandibular joints. Administered as 1–3 weekly injections with effects lasting up to 6 months.
• OSTENIL TENDON Peritendinous injection of 40mg/2ml sodium hyaluronate with mannitol for tendinopathy, supporting tendon gliding and regeneration. Indicated for Achilles, epicondylitis, supraspinatus, patellar, peroneal, and biceps brachii tendons; administered as two weekly injections.
• HAXL One Musculoskeletal viscosupplement product for joint treatment distributed by TRB Chemedica UK as part of its orthopaedic portfolio.
• VISMED Preservative-free hypotonic eye drops containing 0.18% sodium hyaluronate with essential ions matching natural tears, supplied as 20x0.3ml single-dose vials or 10ml multi-dose system. Listed in MIMS as a Gold Standard dry eye treatment.
• VISMED MULTI Multi-dose preservative-free version of VISMED containing 0.18% sodium hyaluronate in a squeezable polymer dispenser (10ml bottle, approximately 250 drops), remaining sterile for up to 90 days after opening.
• VISMED GEL Higher-concentration 0.3% sodium hyaluronate eye drops supplied as 20 single-dose 0.45ml vials. Hypotonic with essential ions and suitable for all contact lens types; targeted at persistent dry eye symptoms.
• VISMED GEL MULTI Multi-dose version of VISMED GEL containing 0.3% sodium hyaluronate in a precise drop-dispenser bottle (10ml, approximately 250 drops), sterile for up to 90 days after opening, for persistent dry eye symptoms.
• VISMED LIGHT Cost-effective mild dry eye solution containing 0.1% sodium hyaluronate with minimal preservatives and pH balanced to natural tears. 15ml multi-dose bottle, suitable for all contact lens types.
• REMOGEN OMEGA Ophthalmology product for dry eye treatment supplied as 20x0.25ml single-dose vials, distributed by TRB Chemedica UK within its ophthalmology range.
• VISCOSEAL Syringe 0.05% sodium-hyaluronate irrigation solution supplied in a 10ml syringe for intra-operative joint irrigation during arthroscopy. Replaces synovial fluid lost during irrigation, restores cartilage metabolism and homeostasis, and accelerates post-operative recovery.
• ArthroZheal PRF Surgical Bioactive matrix product using the Vivostat System for arthroscopic tissue sealing, healing, and regeneration. Can be applied during surgery or as an injectable therapeutic for cartilage, tendon, and ligament repair.

Quantifiable outcome

• OSTENIL treatment cycle effects last 6-12 months
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• UsonocoreChannel Partner/ Reseller/ Distributor · 1 January 2024Distribution partnership for UK market. Usono provides innovative dynamic ultrasound technology, particularly the ProbeFix Dynamic device for functional assessment. Partnership aligns with TRB UK's strategy to expand ultrasound offerings and support sports medicine and rehabilitation practices.
• Clarius Mobile HealthcoreChannel Partner/ Reseller/ Distributor · 1 January 2022Partnership with Canadian developer and manufacturer of wireless handheld ultrasound scanners. TRB UK primarily markets L7 and L15 HD3 scanners for MSK, orthopaedics, and related specialties. The Clarius HD3 range offers high-quality point-of-care ultrasound for diagnostic imaging and procedural guidance.
• Vivostat A/ScoreChannel Partner/ Reseller/ Distributor · 1 January 2022Exclusive Sales & Marketing agreement for ArthroZheal in UK and Ireland. Danish company Vivostat specialises in biotechnology and medical engineering, creating the Vivostat System for arthroscopic surgery applications. ArthroZheal is a bioactive matrix rich in platelet-derived growth factors for tissue sealing and regeneration.
• MindrayminorChannel Partner/ Reseller/ DistributorPartnership for Magic Series portable ultrasound machines. Complementary to Clarius product line for customers seeking additional ultrasound solutions.
• TRB Chemedica International (Parent Company)coreStrategic or Co-development PartnerUK subsidiary of Swiss healthcare group with more than 30 years of experience in developing and marketing research-led pharmaceutical products and medical devices. Parent company manufactures and supplies OSTENIL, VISMED, and other proprietary products to the UK subsidiary.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Contipro: Czech hyaluronic acid manufacturer producing sodium hyaluronate for ophthalmology, orthopaedics and wound care, a direct upstream and product competitor to TRB UK's HA-based OSTENIL and VISMED ranges.
• Vivostat A/S: Danish biotech whose ArthroZheal/Vivostat System PRF technology is distributed by TRB Chemedica UK; comparable in surgical/orthobiologic offering targeting arthroscopic tissue healing in the same UK orthopaedic customer base.
• Fidia Farmaceutici: Italian specialty pharma company producing Hyalgan and Hymovis hyaluronic acid viscosupplements, a direct competitor to OSTENIL in joint injection therapy with overlapping rheumatology and orthopaedic customers.
• Anika Therapeutics: US-based manufacturer of Monovisc and Orthovisc hyaluronic acid viscosupplements for osteoarthritis, a direct competitor in HA-based joint injection therapy sold through orthopaedic channels.
• Santen Pharmaceutical: Japanese specialty ophthalmology company with a significant European dry-eye and ocular-surface franchise, directly comparable to VISMED's preservative-free sodium-hyaluronate eye drops in target prescribers.
• Bioventus: Global orthobiologics company offering Durolane and other hyaluronic acid viscosupplements for osteoarthritis — directly competes with the OSTENIL range in the UK MSK market and shares the same hospital/clinic channel.

Broad incumbents

• Bausch + Lomb: Major ophthalmic goods manufacturer with broad dry-eye and ocular-surface portfolios (e.g., Artelac, Biotrue) competing directly with the VISMED sodium-hyaluronate eye drop range in optometry and ophthalmology channels.
• Arthrex: Global orthopaedic devices and orthobiologics incumbent with a broad arthroscopy and joint-repair portfolio that overlaps with TRB UK's VISCOSEAL irrigation and ArthroZheal surgical offerings in the UK orthopaedic surgery channel.
• Sanofi: Large incumbent pharma whose Synvisc (hylan G-F 20) viscosupplement is a leading competitor to OSTENIL in the UK orthopaedic market, sold through similar NHS and private clinic channels.
• Ferring Pharmaceuticals: Specialty pharma group with a presence in orthopaedics and women's health, operating a broader portfolio that overlaps with TRB UK's hospital-channel sales motion and includes competing orthopaedic/rheumatology products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/trbchemedicauk
• LinkedInlinkedin.com/company/trb-chemedica-uk-ltd
• Instagraminstagram.com/trbchemedicauk

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRB Chemedica UK Ltd